Gross hemoglobinuria and oliguria are common transient complications of sclerotherapy for venous malformations: review of 475 procedures.
OBJECTIVE
The purpose of this article is to study the incidence, risk factors, and treatment of gross hemoglobinuria and oliguria following sclerotherapy for venous malformations.


METHODS
The clinical records and imaging studies of 131 patients with venous malformations (57 male and 74 female patients; age range, 2-58 years) who underwent sclerotherapy at our institution between July 1993 and August 2007 were reviewed. Demographic data, the location and estimated size of the malformation, the type and dose of the sclerosing agents, development of postprocedural hemoglobinuria and oliguria, and the treatment given were documented and analyzed.


RESULTS
Four hundred seventy-five sclerotherapy procedures were performed on 131 patients, with the number of procedures per patient ranging from 1 to 21 (mean, 3.6 procedures). Sodium tetradecyl sulfate was used in 47% of the procedures, ethanol in 27%, and both agents in 26%. Transient hemoglobinuria occurred after 34% of the sclerotherapy procedures, and 57% of these were associated with transient oliguria, with increased risk with higher adjusted doses (sclerosant volume/weight of patient) for both agents. Resolution of the hemoglobinuria and oliguria with hydration, alkalinization, and diuretics occurred in all patients. The risk of hemoglobinuria increased with higher adjusted dose (sclerosant volume/weight of patient) for both agents and with sclerotherapy of venous malformations affecting the lower extremities and multiple locations.


CONCLUSIONS
Transient hemoglobinuria and oliguria are common complications of sclerotherapy for venous malformation. Nevertheless, with proper fluid management, all the patients promptly recovered. The risk correlates with the volume of sclerosant (adjusted to patient's weight) and is higher for lower extremity and multiple locations.
Division of Vascular and Interventional Radiology, Children's Hospital Boston and Harvard Medical School, Boston, MA 02115, USA.
Roger
R
Barranco-Pons
Patricia E
PE
Burrows
Mary
M
Landrigan-Ossar
Cameron C
CC
Trenor
Ahmad I
AI
Alomari
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D000431:Ethanol / Q000627:therapeutic use; D005260:Female; D006456:Hemoglobinuria / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009846:Oliguria / Q000209:etiology*; D012597:Sclerosing Solutions / Q000627:therapeutic use; D015911:Sclerotherapy / Q000009:adverse effects*; D012981:Sodium Tetradecyl Sulfate / Q000627:therapeutic use; D054079:Vascular Malformations / Q000628:therapy*; D014680:Veins / Q000002:abnormalities*; D055815:Young Adult
D012597:Sclerosing Solutions; D000431:Ethanol; D012981:Sodium Tetradecyl Sulfate